Go to deals
Business Support Services | Healthcare | Private Equity

BlijWerkt has been acquired by Mentha Capital

Gilde Healthcare Partners has sold BlijWerkt Groep B.V. to Mentha Capital.

BlijWerkt is a Dutch provider of occupational health services that help companies manage employee absenteeism. The firm reduces the costs of absenteeism by increasing the vitality of client organizations and their employees. It also manages the process of sick leave and reintegration. BlijWerkt combines the power of the bigger players with the flexibility and personal attention of the smaller ones. The company is headquartered in Woerden, the Netherlands and is owned by Gilde Healthcare Partners, a Dutch private equity investor, since 2011. BlijWerkt has a diversified client base and is mainly active in the healthcare, government and educational sectors. The Group’s solutions are a high impact, mandatory service of negligible cost to its clients, which results in recurring revenues of +95%.

Mentha Capital is an independent investment company that focuses on the lower-end of the mid-market in the Benelux. Mentha invests in established, medium-sized and profitable companies that have the opportunity to grow further through a buy-and-build strategy, expansion into new markets or an organizational transition. With more than €400 million under management, Mentha works actively with entrepreneurs to support their companies in realizing their ambitious growth plans.

Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two fund strategies: venture and growth capital and private equity. Gilde Healthcare's venture and growth capital fund invests in health tech and therapeutics. The venture and growth companies are based in Europe and North America. Gilde Healthcare's private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

Oaklins’ team in the Netherlands acted as the exclusive M&A advisor to the shareholders of BlijWerkt Groep B.V., including the majority shareholder Gilde Healthcare Partners.

Service
M&A sell-side
Parties
“We are very grateful to Oakins for their support on this, behind the scenes, complex transaction. They have clearly proven their added value as they were able to quickly understand the essence of the business and structure the process in such a way that it benefited us, but also prospective acquirors. Throughout the process, the Oaklins team has proven to be a dedicated and knowledgeable partner to us.”

Hugo de Bruin

Partner, Gilde Healthcare Partners

Talk to the deal team

 Frederik  van der Schoot

Frederik van der Schoot

Managing Partner

Amsterdam, Netherlands
Oaklins Netherlands
 Felix  Snoeck Henkemans

Felix Snoeck Henkemans

Associate

Amsterdam, Netherlands
Oaklins Netherlands

Related deals

Permali Gloucester has been acquired by Diamorph (subject to regulatory approval)
Private Equity | Aerospace & Defense | Automotive | Industrial Machinery & Components

Permali Gloucester has been acquired by Diamorph (subject to regulatory approval)

Private equity firm 3i Group and the private shareholders of Permali Gloucester Limited have sold their interest in the company to Diamorph.

Learn more
Westiform, ID Néon and Nicklex merge to form WIN Group
Business Support Services

Westiform, ID Néon and Nicklex merge to form WIN Group

The shareholders of Westiform Group have sold their shares to WIN Group, a newly created entity owned by the Hofmann family and consisting of ID Néon and Nicklex, two major players in the visual communication market in Switzerland.

Learn more
BaltCap has sold Labochema to French laboratory supply distributor Dominique Dutscher
Private Equity | Other Industries

BaltCap has sold Labochema to French laboratory supply distributor Dominique Dutscher

BaltCap Lithuania SME Fund has sold its 46% shareholding in Labochema UAB, a Lithuanian laboratory supplies trading company, to Dominique Dutscher. Labochema’s CEO and the chairman also sold their shareholdings. As a result of the transaction, Dominique Dutscher now controls 100% of Labochema.

Learn more